Pacific Biosciences of California, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 5, 2026, reporting financial results for the three and nine months ended September 30, 2026.

Key Highlights

  • Q3 2026 total revenue: $40,564 thousand, up from $38,441 thousand in Q3 2025, according to the filing.
  • Nine-month net loss: $90,862 thousand for the nine months ended September 30, 2026, compared to a net loss of $506,005 thousand for the same period in 2025.
  • Q3 2026 net loss per share: Basic and diluted loss of $0.12, versus $0.13 in Q3 2025.
  • Total assets: $721,096 thousand as of September 30, 2026, down from $784,083 thousand at December 31, 2025.
  • Accumulated deficit: $2,786,164 thousand as of September 30, 2026, the filing disclosed.
  • Settlement charges: $15,400 thousand recorded in the nine months ended September 30, 2026, with no comparable charge in the prior-year period.
  • Shares outstanding: 312,926,730 shares of common stock as of October 31, 2026, per the filing cover page.

Pacific Biosciences Reports Q3 2026 Revenue Growth Alongside Continued Operating Loss

According to the Form 10-Q filed by Pacific Biosciences of California, Inc. (NASDAQ:PACB) for the quarterly period ended September 30, 2026, total revenue for Q3 2026 was $40,564 thousand, consisting of product revenue of $34,002 thousand and service and other revenue of $6,562 thousand. This compares with total revenue of $38,441 thousand in Q3 2025. For the nine months ended September 30, 2026, total revenue was $116,749 thousand versus $115,360 thousand in the prior-year period.

The filing reported gross profit of $13,470 thousand for Q3 2026, compared with $15,901 thousand in Q3 2025. For the nine-month period, gross profit was $38,949 thousand, up from $29,214 thousand in the nine months ended September 30, 2025. Operating expenses for the nine months ended September 30, 2026 included research and development costs of $62,853 thousand, sales, general and administrative expenses of $93,962 thousand, settlement charges of $15,400 thousand, and a gain on disposal of assets of $45,796 thousand. The company reported an operating loss of $89,969 thousand for the nine-month period, compared with an operating loss of $512,664 thousand in the prior-year period, which included $363,708 thousand in amortization of acquired intangible assets and $15,000 thousand in impairment charges.

As of September 30, 2026, the company reported total stockholders' deficit of $61,380 thousand, compared with stockholders' equity of $5,349 thousand at December 31, 2025. The balance sheet reflected convertible senior notes, net, of $643,058 thousand in non-current liabilities, cash and cash equivalents of $55,907 thousand, and investments of $143,511 thousand. Goodwill remained unchanged at $317,761 thousand. Share-based compensation expense for the nine months ended September 30, 2026 was $22,261 thousand, as disclosed in the stockholders' equity statement.

What Was Disclosed

Pacific Biosciences filed its quarterly report covering the three and nine months ended September 30, 2026, disclosing revenue, net loss, balance sheet position, and changes in stockholders' equity, including settlement charges of $15,400 thousand and a $45,796 thousand gain on disposal of assets recorded in the nine-month period.